A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219)
Author:
Affiliation:
1. University of California at Davis, Sacramento, California
2. Southwest Oncology Group Statistical Center, Seattle, Washington
3. University of Michigan Medical Center, Ann Arbor, Michigan
4. University of Colorado, Denver, Colorado
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference13 articles.
1. Muscle-invasive urothelial carcinoma of the bladder;Malkowicz;Urology,2007
2. M-VAC (methotrexate, viblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium;Sternberg;J Urol,1988
3. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;N Engl J Med,2003
4. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC;Millikan;J Clin Oncol,2001
5. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome;Herr;J Clin Oncol,1998
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Perioperative platform for muscle-invasive bladder cancer trials: designs and endpoints;Current Opinion in Urology;2024-09-12
2. Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients;Nature Reviews Clinical Oncology;2023-11-17
3. For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy;European Urology Focus;2023-11
4. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial;Nature Medicine;2023-10-02
5. A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer;European Urology Oncology;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3